Topica Pharmaceuticals announced the enrollment of patients in a Phase 2 clinical trial evaluating luliconazole for the treatment of tinea pedis (athlete’s foot). This multi-center, randomized, double blind trial is evaluating the safety and optimal duration of luliconazole cream 1% administered once daily for 14 or 28 days in approximately 120 patients. The primary efficacy endpoint is to achieve complete clearance of the infection at two weeks post treatment.
Luliconazole is a topical imidiazole antifungal agent being developed for the treatment for a variety of skin and nail fungal infections.
For more information call (650) 473-3800 or visit www.topicapharma.com.